Astellas Pharma (JP:4503) has released an update.
Astellas Pharma Inc. has received European Commission approval for PADCEV (enfortumab vedotin) in combination with KEYTRUDA (pembrolizumab) as a first-line treatment for advanced urothelial cancer. This marks the first time a treatment has shown superiority over the nearly 40-year standard of platinum-containing chemotherapy, based on the global Phase 3 EV-302 trial’s positive survival results. The new regimen offers a significant improvement in median overall and progression-free survival, heralding a new chapter in the management of this often fatal disease.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
